跳至主要内容
临床试验/NL-OMON52861
NL-OMON52861
尚未招募
2 期

[18F]fluor-PEG-folate PET/CT imaging in Giant Cell Arteritis. - Macrophage imaging GCA

niversitair Medisch Centrum Groningen0 个研究点目标入组 10 人待定

概览

阶段
2 期
干预措施
未指定
疾病 / 适应症
未指定
发起方
niversitair Medisch Centrum Groningen
入组人数
10
状态
尚未招募
最后更新
去年

概览

简要总结

暂无简介。

注册库
who.int
开始日期
待定
结束日期
待定
最后更新
去年
研究类型
Observational invasive

研究者

入排标准

入选标准

  • \-Age \>\= 50 years.
  • \-ESR \>\=50 mm/hr (by Westergren method) or CRP \>\= 24\.5 mg/L.
  • \-Clinical symptoms of GCA (at least one of the following): unequivocal cranial
  • symptoms of GCA, symptoms of polymyalgia rheumatica or constitutional symptoms.
  • \-Imaging findings consistent with GCA (at least by one of the following
  • methods): ultrasound, FDG\-PET/CT, MRA or CTA.
  • \-Patients must be able to adhere to the study appointments and other protocol
  • requirements.
  • \-Patients must be capable of giving informed consent and the consent must have
  • been obtained prior to the study related procedures.

排除标准

  • \- Clinical symptoms suggestive of cranial GCA (at least one of the
  • following): new\-onset localized headache, scalp tenderness, temporal
  • artery abnormality (thickening, tenderness, and/or decreased
  • pulsation), ischemia\-related vision loss, stroke, transients ischemic
  • attack, jaw or tongue claudication (pain upon mastication).
  • \- Ultrasound findings consistent with cranial GCA (e.g. halo sign in
  • temporal or facial artery).
  • \- A prior positive temporal artery biopsy.
  • \- Initiation or dose escalation of systemic glucocorticoid therapy (oral,
  • IM, IV) in the 4 weeks prior to inclusion

结局指标

主要结局

未指定

相似试验